埃博拉病毒 VP35 是一种多功能毒力因子。
Ebolavirus VP35 is a multifunctional virulence factor.
机构信息
Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, IA, USA.
出版信息
Virulence. 2010 Nov-Dec;1(6):526-31. doi: 10.4161/viru.1.6.12984. Epub 2010 Nov 1.
Abstract
Ebola virus (EBOV) is a member of the filoviridae family that causes severe hemorrhagic fever during sporadic outbreaks, and no approved treatments are currently available. The multifunctional EBOV VP35 protein facilitates immune evasion by antagonizing antiviral signaling pathways and is important for viral RNA synthesis. In order to elucidate regulatory mechanisms and to develop countermeasures, we recently solved the structures of the Zaire and Reston EBOV VP35 interferon inhibitory domain (IID) in the free form and of the Zaire EBOV VP35 IID bound to dsRNA. Together with biochemical, cell biological, and virological studies, our structural work revealed that distinct regions within EBOV VP35 IID contribute to virulence through host immune evasion and viral RNA synthesis. Here we summarize our recent structural and functional studies and discuss the potential of multifunctional Ebola VP35 as a therapeutic target.
摘要
埃博拉病毒（EBOV）是丝状病毒科的一员，在零星爆发期间会引起严重的出血热，目前尚无批准的治疗方法。多功能的 EBOV VP35 蛋白通过拮抗抗病毒信号通路来促进免疫逃逸，并且对病毒 RNA 合成很重要。为了阐明调控机制并开发对策，我们最近解析了扎伊尔和雷斯顿 EBOV VP35 干扰素抑制结构域（IID）在游离形式和与 dsRNA 结合的扎伊尔 EBOV VP35 IID 的结构。结合生化、细胞生物学和病毒学研究，我们的结构工作表明，EBOV VP35 IID 内的不同区域通过宿主免疫逃逸和病毒 RNA 合成来促进毒力。在这里，我们总结了我们最近的结构和功能研究，并讨论了多功能埃博拉病毒 VP35 作为治疗靶点的潜力。
相似文献
1
Ebolavirus VP35 is a multifunctional virulence factor.埃博拉病毒 VP35 是一种多功能毒力因子。
Virulence. 2010 Nov-Dec;1(6):526-31. doi: 10.4161/viru.1.6.12984. Epub 2010 Nov 1.
2
Structure of the Ebola VP35 interferon inhibitory domain.埃博拉病毒VP35干扰素抑制结构域的结构
Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):411-6. doi: 10.1073/pnas.0807854106. Epub 2009 Jan 2.
3
Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.埃博拉病毒VP35和VP24蛋白对人树突状细胞中全球基因表达的不同时间效应
J Virol. 2015 Aug;89(15):7567-83. doi: 10.1128/JVI.00924-15. Epub 2015 May 13.
4
5
Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins.杆状病毒表达的埃博拉病毒VP35和核蛋白的血清学反应性。
Microbes Infect. 2003 Apr;5(5):379-85. doi: 10.1016/s1286-4579(03)00051-0.
6
Insights into the homo-oligomerization properties of N-terminal coiled-coil domain of Ebola virus VP35 protein.埃博拉病毒 VP35 蛋白 N 端卷曲螺旋结构域同源寡聚化性质的研究进展。
Virus Res. 2018 Mar 2;247:61-70. doi: 10.1016/j.virusres.2018.02.003. Epub 2018 Feb 7.
7
Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells.在植物和哺乳动物细胞中鉴定埃博拉病毒 VP35 蛋白的 RNA 沉默抑制活性。
J Virol. 2012 Mar;86(6):3038-49. doi: 10.1128/JVI.05741-11. Epub 2012 Jan 11.
8
Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain.埃博拉病毒VP35干扰素抑制结构域的表达、纯化、结晶及初步X射线研究。
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Feb 1;65(Pt 2):163-5. doi: 10.1107/S1744309108044187. Epub 2009 Jan 31.
9
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.埃博拉病毒 VP35 识别 dsRNA 和拮抗干扰素的结构基础。
Nat Struct Mol Biol. 2010 Feb;17(2):165-72. doi: 10.1038/nsmb.1765. Epub 2010 Jan 17.
10
Development of RNA aptamers targeting Ebola virus VP35.针对埃博拉病毒 VP35 的 RNA 适体的开发。
Biochemistry. 2013 Nov 26;52(47):8406-19. doi: 10.1021/bi400704d. Epub 2013 Nov 14.
引用本文的文献
1
The Plethora of RNA-Protein Interactions Model a Basis for RNA Therapies.大量的RNA-蛋白质相互作用为RNA疗法奠定了基础。
Genes (Basel). 2025 Jan 2;16(1):48. doi: 10.3390/genes16010048.
2
Aptamers: precision tools for diagnosing and treating infectious diseases.适配体：诊断和治疗传染病的精准工具。
Front Cell Infect Microbiol. 2024 Sep 25;14:1402932. doi: 10.3389/fcimb.2024.1402932. eCollection 2024.
3
Cheminformatics Strategies Unlock Marburg Virus VP35 Inhibitors from Natural Compound Library.化学生信策略从天然化合物库中解锁马尔堡病毒 VP35 抑制剂。
Viruses. 2023 Aug 15;15(8):1739. doi: 10.3390/v15081739.
4
Pathogenicity and Virulence of Ebolaviruses with Species- and Variant-specificity.埃博拉病毒的物种和变体特异性的致病性和毒力。
Virulence. 2021 Dec;12(1):885-901. doi: 10.1080/21505594.2021.1898169.
5
6
To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity.是B还是非B：重组水疱性口炎病毒载体埃博拉病毒糖蛋白疫苗（rVSV-EBOV-GP）的保护机制以及固有免疫和适应性免疫的作用
Microorganisms. 2020 Sep 25;8(10):1473. doi: 10.3390/microorganisms8101473.
7
Ebola Virus Inclusion Body Formation and RNA Synthesis Are Controlled by a Novel Domain of Nucleoprotein Interacting with VP35.埃博拉病毒包含体的形成和 RNA 合成受核蛋白与 VP35 相互作用的新结构域控制。
J Virol. 2020 Jul 30;94(16). doi: 10.1128/JVI.02100-19.
8
Relevance of Ebola virus VP35 homo-dimerization on the type I interferon cascade inhibition.埃博拉病毒VP35同源二聚化对I型干扰素级联反应抑制的相关性
Antivir Chem Chemother. 2019 Jan-Dec;27:2040206619889220. doi: 10.1177/2040206619889220.
9
Ebola Virus Replication Stands Out.埃博拉病毒复制突出。
Trends Microbiol. 2019 Jul;27(7):565-566. doi: 10.1016/j.tim.2019.05.004. Epub 2019 May 30.
10
Ebola virus VP35 has novel NTPase and helicase-like activities.埃博拉病毒 VP35 具有新型 NTPase 和 helicase 样活性。
Nucleic Acids Res. 2019 Jun 20;47(11):5837-5851. doi: 10.1093/nar/gkz340.
本文引用的文献
1
Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.埃博拉病毒 VP35 蛋白中的基本残基是其病毒聚合酶辅助因子功能所必需的。
J Virol. 2010 Oct;84(20):10581-91. doi: 10.1128/JVI.00925-10. Epub 2010 Aug 4.
2
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.用 RNA 干扰对非人类灵长类动物进行埃博拉病毒致死性攻击后的暴露后保护：概念验证研究。
Lancet. 2010 May 29;375(9729):1896-905. doi: 10.1016/S0140-6736(10)60357-1.
3
The chase for the RIG-I ligand--recent advances.追寻 RIG-I 配体——最新进展。
Mol Ther. 2010 Jul;18(7):1254-62. doi: 10.1038/mt.2010.90. Epub 2010 May 11.
4
Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain.雷斯顿埃博拉病毒 VP35 干扰素抑制结构域的结构与功能特征。
J Mol Biol. 2010 Jun 11;399(3):347-57. doi: 10.1016/j.jmb.2010.04.022. Epub 2010 Apr 24.
5
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.埃博拉病毒 VP35 识别 dsRNA 和拮抗干扰素的结构基础。
Nat Struct Mol Biol. 2010 Feb;17(2):165-72. doi: 10.1038/nsmb.1765. Epub 2010 Jan 17.
6
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs.突变使埃博拉病毒的 VP35 蛋白与双链 RNA 的相互作用失效，从而使病毒丧失毒力。
J Virol. 2010 Mar;84(6):3004-15. doi: 10.1128/JVI.02459-09. Epub 2010 Jan 13.
7
Recognition of viruses by cytoplasmic sensors.细胞质传感器对病毒的识别。
Curr Opin Immunol. 2010 Feb;22(1):41-7. doi: 10.1016/j.coi.2009.12.003. Epub 2010 Jan 12.
8
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression.埃博拉病毒 VP35 采用双模策略结合 dsRNA 进行先天免疫抑制。
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):314-9. doi: 10.1073/pnas.0910547107. Epub 2009 Dec 14.
9
Evasion of interferon responses by Ebola and Marburg viruses.埃博拉和马尔堡病毒对干扰素反应的逃避。
J Interferon Cytokine Res. 2009 Sep;29(9):511-20. doi: 10.1089/jir.2009.0076.
10
Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery.扎伊尔埃博拉病毒通过利用宿主的类泛素化修饰机制来阻断I型干扰素的产生。
PLoS Pathog. 2009 Jun;5(6):e1000493. doi: 10.1371/journal.ppat.1000493. Epub 2009 Jun 26.
Zotero 插件